Publications by authors named "R S Bladergroen"
Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the effectiveness of two methods for identifying cancer predisposition syndromes (CPS) in children with newly diagnosed cancers in a Dutch pediatric oncology center.
- Out of 1052 eligible children, 733 underwent both a phenotype-driven approach and a broader phenotype-agnostic gene sequencing, identifying 53 cases of CPS.
- The phenotype-agnostic method revealed more CPS cases, demonstrating that broad genetic sequencing can be more effective than clinical selection based solely on symptoms.
Article Synopsis
- * A comprehensive analysis of 97 BCP-LBL cases revealed a mutational profile closely resembling that of BCP-ALL, though with a higher frequency of mutations in epigenetic modifiers in BCP-LBL.
- * The study found that most molecular subtypes from BCP-ALL are also present in BCP-LBL, suggesting that next-generation sequencing can help identify genetic subtypes in BCP-LBL, potentially